High-Level Overview
Okami Medical is a privately held medical device company developing innovative catheter-based technologies for peripheral vascular occlusion, primarily the LOBO Vascular Occlusion System and complementary Sendero delivery catheters. These products serve interventional radiologists and vascular specialists treating peripheral arterial conditions, solving the problem of inefficient embolization by providing a single-device, rapid-occlusion solution that eliminates the need for multiple coils or plugs, enabling treatment of vessels from 1.5 to 9 mm.[1][2][3][5] The company demonstrates strong growth momentum through sequential FDA 510(k) clearances (LOBO-5 in 2020, LOBO-7/9 in 2022), portfolio expansions like Sendero MAX, and substantial funding: $32.5 million in October 2024 led by Vensana Capital, followed by a $45 million oversubscribed round in 2025 led by Gilde Healthcare, supporting commercialization and clinical programs.[1][2][4][6]
Origin Story
Okami Medical was created in 2017 by Inceptus Medical, a proven medical device incubator with a track record of successes including Inari Medical, Sequent Medical (acquired by Terumo in 2016), and MicroVention (acquired by Terumo in 2006).[2][3][5] Formerly known as Inceptus Newco2 and based in Aliso Viejo, California, the company emerged to address unmet needs in peripheral vascular intervention, leveraging neurovascular-derived technologies like HDBraid.[3][7] Early traction included FDA clearance for LOBO-5 in 2020, expansion to larger sizes in 2022, and leadership transitions: Drew Hykes (former Inari Medical CEO) joined as CEO and President in 2025 alongside board additions like Bill Hoffman as Chairman, Geoff Pardo, and Susana Amorim from Gilde Healthcare.[4][6]
Core Differentiators
- Proprietary HDBraid Technology: Creates an ultra-fine (wires <20 microns thick), highly occlusive pore structure from braided neurovascular design, enabling 90-second average occlusion time with a single device across diverse anatomies, outperforming traditional coils and plugs.[1][2][5][7][8]
- Versatile LOBO System: Four sizes (LOBO-3, -5, -7, -9) treat vessels 1.5-9 mm in a "one-and-done" approach, with low-profile delivery for tortuous paths.[1][2][6]
- Optimized Sendero Catheters: Purpose-built family (Microcatheter, MAX) with hydrophilic coating, stainless steel braid, PTFE liner, and radiopaque markers for precise, low-friction delivery of LOBO occluders, enhancing trackability and procedural efficiency.[2]
- Clinical Validation and Physician Feedback: FDA-cleared devices praised for speed, predictability, and broad applicability, as noted by experts like Dr. Nima Kokabi.[2]
Role in the Broader Tech Landscape
Okami rides the trend of advancing peripheral vascular interventions amid rising vascular disease prevalence, driven by aging populations and demand for minimally invasive embolotherapy.[3][4] Timing aligns with post-pandemic procedural volume recovery and a shift from multi-device embolization to efficient, single-use platforms, fueled by market forces like reimbursement for outpatient procedures and investor interest in medtech (evidenced by back-to-back funding rounds totaling ~$77.5 million).[1][4] By innovating from Inceptus's neurovascular expertise, Okami influences the ecosystem through faster occlusion, reduced procedure times/costs, and expanded treatment options, potentially disrupting a fragmented market dominated by legacy coils.[1][2][5]
Quick Take & Future Outlook
Okami is poised for accelerated commercialization with $45 million fueling U.S. expansion, further LOBO/Sendero iterations, and clinical data generation to capture share in peripheral embolization.[4] Trends like AI-guided imaging and outpatient shifts will amplify its efficient platform, while leadership from Inari alumni positions it for potential acquisition akin to Inceptus peers. Its influence may evolve from niche innovator to category leader, transforming patient outcomes in vascular care as adoption scales. This builds on Okami's core strength: intuitive devices that make complex occlusions routine.[2][4][5]
